Abstract 209P
Background
Immune-cell indices of immunohistochemistry (IHC) are calculated in countless research studies; often to identify prognostic or predictive biomarkers in cancer patients. The study aimed to investigate how the location of immune cells and the amount of tumor epithelia may affect their calculation in breast cancer (BC) patients whilst exploring multiple sample techniques for IHC immune-cell quantification.
Methods
Formalin-fixed, paraffine-embedded pretreatment tumor tissue (N=227; full-cut slides) from BC patients was stained with two multiplexed chromogenic IHC using CK7/19, CD8, CD4, FOXP3, CD20, CD66b, and CD68. AI-powered image analysis (U-net) determined their area-based indices in the reference spaces: total tumor area, tumor stroma, tumor epithelia, a stromal tumor brim, and a fixed area for each lesion using multiple subsamples (mean no., 100) within tumor stroma (in total, 1 mm2) and epithelia (in total, 1 mm2).
Results
Immune cells were predominantly situated in tumor stroma and rarely epithelia (P<0.01). The most infiltrative cell type was CD68 with a mean index of 3% for epithelia, yet 32% for stroma. In remainder cells, indices were <0.7% for epithelia. The amount of epithelia ranged from 1-60%, which strongly affected index calculations that included the total area of epithelia (P<0.01). In addition, solidity of tumor islands was highly associated with the number of infiltrative CD8, CD66b, and CD68 cells (P<0.01).
Conclusions
The location (stroma vs epithelia) of each immune cell of interest should be considered in connection to its index calculation because the amount of tumor epithelia may skew the result. Alternatively, the novel, unbiased subsampling developed in this study could be used. High solidity meant fewer infiltrating cells, which, conceivably, may affect both prognostic and predictive utility of immune cells.
Legal entity responsible for the study
The authors.
Funding
Danish Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract